<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366375</url>
  </required_header>
  <id_info>
    <org_study_id>19.03.15-58-56</org_study_id>
    <nct_id>NCT04366375</nct_id>
  </id_info>
  <brief_title>Pentraxin-3 in Hysterectomy Patients</brief_title>
  <official_title>Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the Tissue Trauma Markers Following Total Laparoscopic Hysterectomy vs Total
      Abdominal Hysterectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute trauma and major surgeries activate a series of cascades to evoke systemic inflammatory
      response. The magnitude of the resulting inflammatory response is proportional to the
      severity of the tissue trauma. Abdominal or laparoscopic technique is widely used for the
      purpose of hysterectomy surgery. It is crucial for many aspects to compare these two
      techniques of hysterectomy in terms of the surgery-induced trauma.

      In this study, the severity of the inflammatory response resulting from the tissue trauma due
      to the techniques of TLH+BSO and TAH+BSO applied in our department were compared based on the
      PTX-3 molecule.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Actual">December 7, 2015</completion_date>
  <primary_completion_date type="Actual">December 7, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pentraxin-3 level</measure>
    <time_frame>Before 24 hours preoperatively and upto 24 hours postoperatively</time_frame>
    <description>Pentraxin-3 ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(NLR)</measure>
    <time_frame>Up to 24 hours postoperative</time_frame>
    <description>neutrophile/lymphocyte ratio</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Laparoscopic Hysterectomy</condition>
  <condition>Abdominal Hysterectomy</condition>
  <arm_group>
    <arm_group_label>TLH+BSO</arm_group_label>
    <description>Total Laparoscopic Hysterectomy + Bilateral Salpingo-Oophorectomy N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAH + BSO</arm_group_label>
    <description>Total Abdominal Hysterectomy + BSO N=20</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PTX-3</intervention_name>
    <description>Pentraxin-3 ng/mL PTX-3 levels were measured using human PTX3 ELISA Kit 96 Tests/Box (Cat. No: CK-E90303) (Hangzhou Eastbiopharm Co.,Ltd., PRC) read by a ELISA device matching with the kit. For the purpose of measurement, microplate washer RT 2600 device and Rayto microplate reader RT 2100C device were used.</description>
    <arm_group_label>TAH + BSO</arm_group_label>
    <arm_group_label>TLH+BSO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum blood samples for each participant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 40 patients, composed of 20 TLH+BSO patients and 20 TAH+BSO patients were
        included into the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ·TLH+BSO patients and TAH+BSO patients

        Exclusion Criteria:

          -  History of a chronic disease (coronary artery disease, diabetes mellitus,
             hypertension, coronary liver failures, chronic kidney disease, chronic respiratory
             diseases, connective tissue disorders) which may affect levels of PTX-3 and other
             inflammatory markers.

          -  Prior surgery due to malignancy.

          -  History of an intra-abdominal surgery, except for cesarean section.

          -  History of any disease which may lead to intra-abdominal adhesions (endometriosis,
             past pelvic infection).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>TLH+BSO and TAH+BSO applied patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak SEZGİN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mugla Sıtkı Kocman University Faculty of Medicine</affiliation>
  </overall_official>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Burak Sezgin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pentraxin-3</keyword>
  <keyword>tissue trauma</keyword>
  <keyword>hysterectomy</keyword>
  <keyword>neutrophil to lymphocyte ratio</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

